caa a22 4500 605491402 CHVBK 20210128100510.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10147-015-0819-2 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0819-2 Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0) [Elektronische Daten] [Yuji Murakami, Ippei Takahashi, Ikuno Nishibuchi, Yoshiko Doi, Tomoyuki Okabe, Masahiro Kenjo, Tomoki Kimura, Yasushi Nagata] Background: The long-term outcomes of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer without regional and distant metastasis were retrospectively analyzed. Methods: Patients with histologically confirmed esophageal submucosal cancers without regional and distant metastasis who received definitive concurrent chemoradiotherapy from 2001 to 2011 were included. Radiation therapy of a median total dose of 60Gy/30 fractions (range, 54-66Gy) with elective nodal irradiation of 40Gy was combined concurrently with 5-furuorouracil-based chemotherapy. Results: Thirty-six patients (33 men and 3 women) aged from 45 to 80years (median, 67 years) were assessed. All patients had squamous cell carcinoma. With a median follow-up time of 61months, the 5-year overall survival, disease-free survival, and locoregional failure-free survival rates were 86% [95% confidence interval (CI), 74-99%], 59% (95% CI, 42-77%), and 90% (95% CI, 79-100%), respectively. Late toxicities of grade 3 pleural effusion in 2 patients, grade 4 pericardial effusion in 1 patient, and grade 5 pneumonitis in 1 patient were observed. Metachronous esophageal cancer was observed in 8 patients (22%). Among them, 6 patients with mucosal legions were salvaged by endoscopic resection. Conclusion: Our long-term results of concurrent chemoradiotherapy (CCRT) for patients with esophageal submucosal cancer showed acceptable toxicities and favorable locoregional control and survivals while maintaining organ preservation. Japan Society of Clinical Oncology, 2015 Esophageal cancer nationallicence Submucosal cancer nationallicence Chemoradiotherapy nationallicence Murakami Yuji Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut Takahashi Ippei Department of Radiation Oncology, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, 1-9-6 Senda-machi, Naka-ku, 730-8619, Hiroshima, Japan aut Nishibuchi Ikuno Department of Radiation Oncology, Hiroshima Prefectural Hospital, Ujinakanda Minami-ku, 734-8530, Hiroshima, Japan aut Doi Yoshiko Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut Okabe Tomoyuki Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut Kenjo Masahiro Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut Kimura Tomoki Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut Nagata Yasushi Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 897-904 1341-9625 20:5<897 2015 20 10147 https://doi.org/10.1007/s10147-015-0819-2 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0819-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Murakami Yuji Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut NATIONALLICENCE 700 1- Takahashi Ippei Department of Radiation Oncology, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, 1-9-6 Senda-machi, Naka-ku, 730-8619, Hiroshima, Japan aut NATIONALLICENCE 700 1- Nishibuchi Ikuno Department of Radiation Oncology, Hiroshima Prefectural Hospital, Ujinakanda Minami-ku, 734-8530, Hiroshima, Japan aut NATIONALLICENCE 700 1- Doi Yoshiko Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut NATIONALLICENCE 700 1- Okabe Tomoyuki Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut NATIONALLICENCE 700 1- Kenjo Masahiro Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut NATIONALLICENCE 700 1- Kimura Tomoki Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut NATIONALLICENCE 700 1- Nagata Yasushi Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 897-904 1341-9625 20:5<897 2015 20 10147